

On the Synthesis and Reactivity of Enantiopure Azetidines

Emilie Banide,^[a] Vincent Lemau de Talancé,^[a] Grégory Schmidt,^[a] Hodney Lubin,^[a] Sébastien Comesse,^{[a],‡} Luc Dechoux,^[a] Louis Hamon,^[a] and Catherine Kadouri-Puchot*^[a]

Keywords: Azetidines / Bromocyclization / Amino alcohols / Vinylsilane / Vinyl bromide / Cyclization

β -Amino alcohols with an (*E*)-vinylsilane moiety were cyclized in the presence of *N*-bromosuccinimide to afford diastereomerically pure azetidines. The chemo- and stereoselectivities of this bromocyclization are discussed. AM1 calcula-

tions support the observed chemoselectivity. The reactivity of the azetidines towards fluorinated reagents was studied.

(© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2007)

Introduction

The electrophile-induced intramolecular cyclization between a heteroatom and an olefin is a well-known process to synthesize various oxygen^[1] or nitrogen^[2] heterocycles. It was expected that the presence of a silyl substituent on the double bond could influence the regioselectivity of such cyclizations. Thus, functionalized vinylsilanes are recognized to favour *exo* processes for the formation of cyclic ethers^[3] and amines.^[4] Indeed, the cyclization of homoallylic alcohols substituted by a vinylsilane terminator led to the regioselective formation of oxetanes,^[3f] and the cyclization of δ -amino vinylsilanes allowed the regioselective synthesis of pyrrolidines.^[4a] To date, electrophile-induced intramolecular cyclizations of homoallylic amino vinylsilanes to obtain azetidine rings have not been reported.

In the course of our studies about the enantioselective synthesis of pipecolic acid^[5a] and proline^[5b] derivatives from unsaturated and silylated β -amino alcohols,^[5c] we focused on the use of these electrophile-induced cyclizations to produce azetidines.^[6] These molecules are attractive synthetic targets because of their use as ligands, their presence in natural products and their potent biological and pharmaceutical activities.^[7] As a consequence, the asymmetric synthesis of these compounds has attracted much attention in recent years.^[8]


In the present study, we explored the scope and the limits of the cyclizations of amino alcohols with a γ -vinylsilane group by using *N*-bromosuccinimide as the electrophilic

reagent. We also describe the transformations of the resulting azetidines into various heterocycles and new amino alcohols.

Results and Discussion

Formation of Azetidines

Amino alcohols **1a–d** and their *O*-methyl derivatives **2a–d** were cyclized by their treatment with *N*-bromosuccinimide to afford azetidines **3a–d** and **4a–d**, respectively, and some recovered starting material (Scheme 1). These reactions occurred in a regio- and diastereoselective manner, and the configurations of the resulting stereogenic centres have been established by X-ray analysis of compound **3d**^[6] and **4d**.^[9] The best experimental conditions were: addition of 1.05 equiv. of *N*-bromosuccinimide to a 0.1 M solution of **1** or **2** at 0 °C in acetonitrile.^[10]




Scheme 1.

Azetidines **3** and **4** were formed in moderate to good yields as single diastereomers. The diastereoselective formations of azetidines **3** and **4** were interpreted by considering the intramolecular attack of the nitrogen atom on the bromonium intermediate **A**, affording a 4-*exo-tet* cyclization product (Scheme 2).^[11]

[a] Université Pierre et Marie Curie-Paris 6 Laboratoire de Chimie Organique UMR 7611, Institut de Chimie Moléculaire FR 2769, Equipe Synthèse Asymétrique, 4 place Jussieu, case courrier 47, 75005 Paris, France
Fax: +33-1-4427-2620
E-mail: kadouri@ccr.jussieu.fr

[‡] Present address: URCOM, Université du Havre, 76600 Le Havre

Supporting information for this article is available on the WWW under <http://www.eurjoc.org> or from the author.




Scheme 2.

Calculations have been performed to obtain some information on the site selectivity of the bromination with respect to the two faces of the vinylsilane. Although *ab initio* calculations (STO3G) ascertained the traditional almost symmetrical alkene-bromonium structure, semi-empirical AM1 calculations^[12,13] led to a very unsymmetrical α -bromo- β -cationic structure (Figure 1). Such a situation seemed to account for the strong hyperconjugation between the C_α -Si bond and the empty p orbital on the cationic C_β atom.^[14] Evidence for this well-known effect was given by the unusual length (ca. 2.37 Å) of the C_α -Si bond. Discrimination between the attack of Br^+ on either side of the double bond arose from a quite important (3.4 kcal/mol) energy difference between the two stereoisomers; the attack on the bromine atom occurred

on the side of the $\text{C}=\text{C}$ bond opposite the incoming nitrogen atom. As a result, two conformations of the vinylsilane corresponding to the two different diastereomeric cations **A** and **B** showed different steric interactions particularly with the α -(hydroxymethyl)benzyl moiety.^[15] Moreover, progress towards the cyclized products did not show any further steric hindrance. Indeed, calculations still confirmed an energy difference of 2.9 kcal/mol between the cyclized azetidinium compounds **C** and **D** (Figure 2). The energy difference may be explained by the pyramidalisation of C_β , spreading the $\text{C}_\alpha\text{HBr-SiMe}_3$ and phenyl groups apart and decreasing the associated steric hindrance.

Because of the presence of different heteroatoms (bromine, silicon, oxygen and nitrogen), these azetidines dis-

Figure 1. AM1-calculated structures for both **A** (favored) and **B** (disfavored) bromonium ions.Figure 2. AM1-calculated structures for both **C** (favored) and **D** (disfavored) azetidinium ions.

closed a very intriguing reactivity upon their interaction with fluorinated reagents.

Reaction of Azetidines with Tetrabutylammonium Fluoride

Compounds **3** and **4** were treated with tetrabutylammonium fluoride in dry THF. Whereas amino ethers **4** were desilylated to afford a complex mixture of products,^[16,17] azetidines **3**, under the same conditions gave bicyclic compounds **5**. The product **5a** (R = Ph) was recrystallized and an X-ray analysis^[18] of this compound (Figure 3) showed a *cis* relative configuration for each heterocycle, thus establishing an (*S*) absolute configuration at the ring junction (Scheme 3).






Figure 3. X-ray structure of **5a**.



Scheme 3.

From a mechanistic point of view, the intramolecular cyclization described above can be viewed as a simple desilylation by the fluoride ion, generating a negative charge on the carbon atom. The resulting carbenoid may evolve through a subsequent acid/base reaction in an inter- or intramolecular manner with the hydroxy group, and further displacement of the bromine atom by the alcoholate in an S_N2-type reaction can occur. The integrity of the stereogenic centre at the ring junction was not altered by this process. (Scheme 4).


Interestingly, when the hydroxy function of the starting material was protected in **4** (R' = CH₃), no cyclization could occur; a mixture of products resulting probably from the non-selective reactivity of the carbenoid species at the workup stage was observed. We decided then to test the desilylation under acidic conditions.



Scheme 4.


Reaction of Azetidines with HF/Pyridine

Surprisingly, azetidines **3** and **4** reacted with a mixture HF/pyridine to lead to the amino alcohols **6** and **7**, respectively, bearing a (*Z*)-bromovinyl function, in good to excellent yields (Scheme 5).




Scheme 5.

This totally stereoselective reaction might take place, by an E2 mechanism; protonation of the nitrogen atom would give the ammonium intermediate **E**, and opening of the azetidine ring in an *anti* elimination by attack of the fluoride ion on the TMS group would result in the selective formation of the (*Z*) isomer (Schemes 5 and 6).^[19] Likewise, the β-elimination of N₃SiMe₃^[20] and BrSiMe₃^[21] are known to take place with *anti* stereochemistry. In contrast, ring-opening elimination^[22] or substitution^[23] of four-membered cyclic ammonium ions have been only scarcely described.



Scheme 6.

Next, in order to obtain the free azetidines, we focused on their hydrogenolysis. This reaction was tested on compound **3d**, which reacted with hydrogen to afford product **8**. Two reactions occurred under these conditions: a debenzoylation and a hydrodehalogenation, as indicated in Scheme 7.



Scheme 7.

This result shows that it is possible to synthesize in four steps, starting from phenyl glycinol, enantiopure *cis*-2,4-di-alkylated azetidines.

Conclusions

We have described the one-pot formation of polysubstituted enantiopure azetidines by a totally regio- and diastereoselective *N*-bromosuccinimide-induced intramolecular cyclization. These compounds show their highly stimulating reactivity when submitted to various reagents. The new β -amino alcohols possessing a bromovinyl function are potential intermediates for the synthesis of new heterocycles. Studies are underway to elucidate the mechanistic peculiarities of the behaviour of these azetidines.

Experimental Section

General Methods: ^1H and ^{13}C NMR spectra (CDCl_3 solution) were recorded with a Bruker ARX 250 spectrometer at 250 MHz and 62.9 MHz, respectively; chemical shifts are reported in ppm from TMS. Optical rotations were determined with a Perkin–Elmer 141 instrument. All reactions were carried out under argon. Column chromatography was performed with silica gel (230–400 mesh) by using various mixtures of ethyl acetate (AcOEt) or diethyl ether (Et_2O) and cyclohexane (CH). Melting points are uncorrected. THF was distilled from sodium/benzophenone ketyl. Compositions of stereoisomeric mixtures were determined by NMR analysis of crude products before any purification.

General Procedure for the Methylation of Amino Alcohols: A solution of amino alcohol (1.6 mmol) in anhydrous THF (3 mL) was added to a solution of sodium hydride (2 mmol) in THF (12 mL) at 0 °C. After stirring at room temp. for 1.5 h, iodomethane (4.1 mmol) was added dropwise and the mixture was stirred until the complete disappearance of the starting material. After addition of water, extraction with Et_2O was followed by drying the organic layers with MgSO_4 . After concentration under reduced pressure, the crude material was purified by chromatography with silica gel (CH/AcOEt , 95:5) to give the amino ethers.

[(1*R*,2*R*)-2-methoxy-1-phenylethyl][(1*R*,3*E*)-1-phenyl-4-(trimethylsilyl)but-3-en-1-yl]amine (2a): Oil (384 mg, 68% yield). ^1H NMR (250 MHz, CDCl_3): δ = 7.22–7.06 (m, 10 H, Ar), 5.87 (dt, J = 6.5 and 18.5 Hz, 1 H, $\text{CH}=\text{CHTMS}$), 5.70 (d, J = 18.5 Hz, 1 H, $\text{CH}=\text{CHTMS}$), 3.92 (dd, J = 4.5 and 7.0 Hz, 1 H, NCHPh), 3.72 (t, J = 6.5 Hz, 1 H, NCHPh), 3.50–3.40 (m, 2 H, CH_2O), 3.23 (s, 3 H, OCH_3), 2.46 (dt, J = 3.5 and 6.5 Hz, 2 H, CH_2), 2.26 (s, 1 H, NH), 0.0 (s, 9 H, TMS) ppm. ^{13}C NMR (62.9 MHz, CDCl_3): δ = 144.5 (Ar), 143.3 ($\text{CH}=\text{CHTMS}$), 141.7 (Ar), 133.8 ($\text{CH}=\text{CHTMS}$), 128.1, 128.0, 127.7, 127.1, 127.0, 126.6 (Ar), 77.0 (CH_2O), 60.6 (OCH_3), 60.2 (NCHPh), 58.9 (NCHPh), 44.7 (CH_2), –1.2 (TMS) ppm. $\text{C}_{22}\text{H}_{31}\text{NOSi}$ (353.57): calcd. C 74.73, H 8.84, N 3.96; found C 74.63, H 10.22, N 3.37.

[(1*R*,2*R*)-2-methoxy-1-phenylethyl][(1*S*,3*E*)-1-propyl-4-(trimethylsilyl)but-3-en-1-yl]amine (2b): Oil (306 mg, 60% yield). $[\alpha]_{\text{D}}^{20}$ = –83 (c = 1.0, CHCl_3). ^1H NMR (250 MHz, CDCl_3): δ = 7.34–7.15 (m, 5 H, Ar), 5.92 (dt, J = 7.0 and 18.5 Hz, 1 H, $\text{CH}=\text{CHTMS}$), 5.67 (d, J = 18.5 Hz, 1 H, $\text{CH}=\text{CHTMS}$), 4.00 (dd, J = 5.0 and 7.5 Hz, 1 H, NCHPh), 3.33 (m, 2 H, CH_2O), 3.27 (s, 3 H, OCH_3), 2.38 (dt, J = 7.5 and 17.5 Hz, 1 H, NCH-Pr), 2.19 (t, J = 5.0 Hz, 2 H, $\text{CH}_2\text{C}=\text{C}$), 1.75 (s, 1 H, NH), 1.40–1.23 (m, 1 H, CHHCH_2), 1.23–1.14 (m, 3 H, CHHCH_2), 0.71 (t, J = 6.0 Hz, 3 H, CH_3), 0.0 (s, 9 H, TMS) ppm. ^{13}C NMR (62.9 MHz, CDCl_3): δ = 143.5 ($\text{CH}=\text{CHTMS}$), 141.8 (Ar), 133.6 ($\text{CH}=\text{CHTMS}$), 128.4, 127.9, 127.4 (Ar), 78.3 (CH_2O), 59.8 (NCHPh), 58.8 (OCH_3), 53.3 (NCH-Pr), 40.5 (CH_2), 37.7 (CH_2), 19.2 (CH_2), 14.3 (CH_3), –1.1 (TMS)

ppm. $\text{C}_{19}\text{H}_{33}\text{NOSi}$ (319.56): calcd. C 71.41, H 10.41, N 4.38; found C 71.12, H 10.65, N 4.14.

[(1*R*,3*E*)-1-isopropyl-4-(trimethylsilyl)but-3-en-1-yl][(1*R*)-2-methoxy-1-phenylethyl]amine (2c): Oil (434 mg, 85% yield). $[\alpha]_{\text{D}}^{20}$ = –87 (c = 0.9, CHCl_3). ^1H NMR (250 MHz, CDCl_3): δ = 7.34–7.14 (m, 5 H, Ar), 5.94 (dt, J = 7.5 and 17.5 Hz, 1 H, $\text{CH}=\text{CHTMS}$), 5.67 (d, J = 17.5 Hz, 1 H, $\text{CH}=\text{CHTMS}$), 3.98 (t, J = 7.5 Hz, 1 H, NCHPh), 3.33–3.28 (m, 2 H, CH_2O), 3.27 (s, 3 H, OCH_3), 2.24–2.15 (m, 3 H, NCH-iPr and CH_2), 1.69 (s, 1 H, NH), 1.52–1.45 [m, 1 H, $\text{CH}(\text{CH}_3)_2$], 0.78 (d, J = 10 Hz, 3 H, CH_3), 0.75 (d, J = 10 Hz, 3 H, CH_3), 0.0 (s, 9 H, TMS) ppm. ^{13}C NMR (62.9 MHz, CDCl_3): δ = 144.4 ($\text{CH}=\text{CHTMS}$), 142.0 (Ar), 133.0 ($\text{CH}=\text{CHTMS}$), 128.2, 128.1, 127.3 (Ar), 78.3 (CH_2O), 60.3 (NCHPh), 59.6 (NCH-iPr), 58.8 (OCH_3), 37.8 (CH_2), 31.0 (CHMe_2), 19.2 (CH_3), 18.6 (CH_3), –1.0 (TMS) ppm. $\text{C}_{19}\text{H}_{33}\text{NOSi}$ (319.56): calcd. C 71.41, H 10.41, N 4.38; found C 70.61, H 10.47, N 4.13.

[(1*R*,3*E*)-1-tert-butyl-4-(trimethylsilyl)but-3-en-1-yl][(1*R*)-2-methoxy-1-phenylethyl]amine (2d): Oil (469 mg, 88% yield). $[\alpha]_{\text{D}}^{20}$ = –101 (c = 1.0, CHCl_3). ^1H NMR (250 MHz, CDCl_3): δ = 7.15–7.32 (m, 5 H, Ar), 6.06 (dt, J = 6.5 and 18.5 Hz, 1 H, $\text{CH}=\text{CHTMS}$), 5.63 (d, J = 18.5 Hz, 1 H, $\text{CH}=\text{CHTMS}$), 4.07 (dd, J = 4.5 and 8.5 Hz, 1 H, NCHPh), 3.43–3.32 (m, 2 H, CH_2O), 3.31 (s, 3 H, OCH_3), 2.50–2.42 (m, 1 H, $\text{CHH C}=\text{C}$), 2.21–1.94 (m, 2 H, $\text{CHHC}=\text{C}$ and $t\text{BuCH}$), 1.59 (s, 1 H, NH), 0.77 (s, 9 H, $t\text{Bu}$), 0.0 (s, 9 H, TMS) ppm. ^{13}C NMR (62.9 MHz, CDCl_3): δ = 146.9 ($\text{CH}=\text{CHTMS}$), 141.6 (Ar), 130.9 ($\text{CH}=\text{CHTMS}$), 128.6, 128.2, 127.4 (Ar), 78.4 (CH_2O), 62.2 ($\text{NCH}t\text{Bu}$), 60.1 (NCHPh), 58.9 (OCH_3), 39.0 (CH_2), 35.4 (CMe_3), 27.4 (CMe_3), –1.1 (TMS) ppm. $\text{C}_{20}\text{H}_{35}\text{NOSi}$ (333.58): calcd. C 72.01, H 10.58, N 4.20; found C 71.98, H 10.59, N 4.39.

General Procedure for the Syntheses of Azetidines 3 and 4: *N*-Bromosuccinimide (0.23 mmol) was added at 0 °C to a solution of the required amino alcohol (0.21 mmol) in acetonitrile (4 mL). The mixture was stirred at 0 °C for 15 min, and aqueous NaOH (10%, 3 mL) was added. The aqueous layer was extracted with Et_2O , and the organic layers were combined, dried with MgSO_4 and concentrated under reduced pressure. The residue was then chromatographed on silica gel.

(2*R*)-2-{(2*S*,4*R*)-2-[(1*S*)-(Bromo)(trimethylsilyl)methyl]-4-phenylazetidin-1-yl}-2-phenylethanol (3a): White solid (66 mg, 75% yield). M.p. 87 °C. $[\alpha]_{\text{D}}^{20}$ = 20 (c = 2.5, CHCl_3). ^1H NMR (250 MHz, CDCl_3): δ = 7.38–7.35 (m, 2 H, Ar), 7.19–7.04 (m, 6 H, Ar), 6.91–6.85 (m, 2 H, Ar), 3.75–3.67 (m, 2 H, CHBr and CHHO), 3.49 (dd, J = 4.5 and 8.3 Hz, 1 H, CHHO), 3.36–3.06 (m, 4 H, NCHCBr , 2 NCHPh and OH), 2.12–1.86 (m, 2 H, CCH_2C), 0.0 (s, 9 H, TMS) ppm. ^{13}C NMR (62.9 MHz, CDCl_3): δ = 143.8, 135.6, 129.4, 128.5, 128.4, 128.1, 127.7, 127.6 (Ar), 67.3 (NCHPh), 62.6 (CH_2O), 60.8 (CHCBr), 58.7 (NCHPh), 49.1 (CBr), 32.1 (CH_2), –2.1 (TMS) ppm. $\text{C}_{21}\text{H}_{28}\text{BrNOSi}$ (418.44): calcd. C 60.28, H 6.74, N 3.35; found C 60.25, H 6.82, N 3.31.

(2*R*)-2-{(2*S*,4*S*)-2-[(1*S*)-(Bromo)(trimethylsilyl)methyl]-4-propylazetidin-1-yl}-2-phenylethanol (3b): White solid (36.3 mg, 45% yield). M.p. 58 °C. $[\alpha]_{\text{D}}^{20}$ = –36 (c = 1.15, CHCl_3). ^1H NMR (250 MHz, CDCl_3): δ = 7.32–7.09 (m, 5 H, Ar), 3.75–3.52 (m, 3 H, CHBr and CH_2O), 3.52–3.35 (m, 1 H, NCHPh), 3.25–3.05 (m, 1 H, NCHCBr), 3.05–2.85 (m, 1 H, NCHPr), 1.73 (t, J = 7.8 Hz, 2 H, CHCH_2CH), 1.50–0.85 (m, 4 H, 2 CH_2), 0.71 (t, J = 7.3 Hz, 3 H, CH_3), 0.0 (s, 9 H, TMS) ppm. ^{13}C NMR (62.9 MHz, CDCl_3): δ = 136.9, 129.2, 128.5, 128.1 (Ar), 67.4 (NCHPh), 63.4 (CH_2O), 59.6 (CHBr), 58.2 (NCHCBr), 48.9 (NCHPr), 38.5 (CH_2), 27.5 (CH_2), 18.3 (CH_2), 14.2 (Me), –2.0 (TMS) ppm. $\text{C}_{18}\text{H}_{30}\text{BrNOSi}$ (384.43): calcd. C 56.24, H 7.87, N 3.64; found C 56.44, H 8.15, N 3.65.

(2R)-2-[(2S,4S)-2-[(1S)-(Bromo)(trimethylsilyl)methyl]-4-isopropylazetidin-1-yl]-2-phenylethanol (3c): White solid (44.4 mg, 55% yield). M.p. 63 °C. $[\alpha]_D^{20} = -44$ ($c = 1.18$, CHCl_3). ^1H NMR (250 MHz, CDCl_3): $\delta = 7.56\text{--}7.03$ (m, 5 H, Ar), 3.66–3.51 (m, 3 H, CHBr and CH_2O), 3.37–3.28 (m, 2 H, NCHPh and OH), 3.02 (td, $J = 2.3$ and 8.0 Hz, 1 H, NCHCBr), 2.84–2.76 (m, 1 H, NCHiPr), 1.81 (q, $J = 7.5$ Hz, 1 H, CHCHHCH), 1.46–1.23 (m, 2 H, CHCHHCH and CHMe_2), 0.86 (d, $J = 5.0$ Hz, 3 H, Me), 0.47 (d, $J = 5.0$ Hz, 3 H, Me), 0.0 (s, 9 H, TMS) ppm. ^{13}C NMR (62.9 MHz, CDCl_3): $\delta = 137.2$, 129.1, 128.5, 128.1 (Ar), 68.3 (NCHPh), 64.1 (NCHiPr), 63.8 (CH_2O), 59.3 (NCH), 49.1 (CHBr), 31.0 [$\text{CH}(\text{Me})_2$], 21.8 (CH_2), 18.8 (Me), 17.0 (Me), –2.0 (TMS) ppm. $\text{C}_{18}\text{H}_{30}\text{BrNOSi}$ (384.43): calcd. C 56.24, H 7.87, N 3.64; found C 56.74, H 8.08, N 3.07.

(2R)-2-[(2S,4S)-2-[(1S)-(Bromo)(trimethylsilyl)methyl]-4-tert-butylazetidin-1-yl]-2-phenylethanol (3d): White solid (44.3 mg, 53% yield). M.p. 71 °C. $[\alpha]_D^{20} = -106$ ($c = 0.8$, CHCl_3). ^1H NMR (250 MHz, CDCl_3): $\delta = 7.25\text{--}6.95$ (m, 5 H, Ar), 3.75 (t, $J = 10.5$ Hz, 1 H, CHHO), 3.55 (m, 2 H, CHBr and OH), 3.43–3.28 (m, 2 H, CHHO and NCHPh), 3.21 (td, $J = 2.3$ and 8.0 Hz, 1 H, NCHCBr), 2.66 (t, $J = 8.3$ Hz, 1 H, CHtBu), 1.80 (q, $J = 7.5$ Hz, 1 H, CHCH_2CH), 1.53–1.43 (m, 1 H, CHCH_2CH), 0.67 (s, 9 H, tBu), 0.0 (s, 9 H, TMS) ppm. ^{13}C NMR (62.9 MHz, CDCl_3): $\delta = 136.6$, 129.6, 128.5, 128.1 (Ar), 68.2 (NCHtBu), 66.3 (NCHPh), 62.7 (CH_2O), 58.0 (NCH), 48.5 (CHBr), 34.1 (CMe_3), 27.0 (CMe_3), 24.0 (CH_2), –2.0 (TMS) ppm. $\text{C}_{19}\text{H}_{32}\text{BrNOSi}$ (398.45): calcd. C 57.27, H 8.09, N 3.52; found C 57.33, H 8.23, N 3.41.

(2S,4R)-2-[(1S)-(Bromo)(trimethylsilyl)methyl]-1-[(1R)-2-methoxy-1-phenylethyl]-4-phenylazetidine (4a): Oil (47.2 mg, 52% yield). ^1H NMR (250 MHz, CDCl_3): $\delta = 7.15\text{--}7.11$ (m, 2 H, Ar), 6.92–6.81 (m, 8 H, Ar), 3.75–3.53 (m, 4 H, NCHPh , CHHO , NCHCBr and CHBr), 3.32 (dt, $J = 2.5$ and 7.5 Hz, 1 H, NCHPh), 3.17 (dd, $J = 5.0$ and 10.0 Hz, 1 H, CHHO), 3.11 (s, 3 H, OMe), 2.04 (t, $J = 7.5$ Hz, 2 H, CHCH_2CH), 0.0 (s, 9 H, TMS) ppm. ^{13}C NMR (62.9 MHz, CDCl_3): $\delta = 144.4$, 137.8, 128.9, 127.9, 127.7, 127.5, 127.3, 126.6 (Ar), 76.6 (CH_2O), 70.2 (NCHPh), 64.2 (NCHCBr), 61.6 (NCHPh), 58.6 (OMe), 50.9 (CHBr), 31.9 (CH_2), –2.0 (TMS) ppm. $\text{C}_{22}\text{H}_{30}\text{BrNOSi}$ (432.47): calcd. C 61.10, H 6.99, N 3.24; found C 60.82, H 7.78, N 2.68.

(2S,4S)-2-[(1S)-(Bromo)(trimethylsilyl)methyl]-1-[(1R)-2-methoxy-1-phenylethyl]-4-propylazetidine (4b): Solid (32.6 mg, 39% yield). M.p. 44 °C. $[\alpha]_D^{20} = -45$ ($c = 1.0$, CHCl_3). ^1H NMR (250 MHz, CDCl_3): $\delta = 7.19\text{--}7.12$ (m, 5 H, Ar), 3.58–3.47 (m, 3 H, NCHPh , CHHO and CHBr), 3.30 (dt, $J = 1.5$ and 9.5 Hz, 1 H, NCHCBr), 3.19 (dd, $J = 2.0$ and 7.2 Hz, 1 H, CHHO), 3.15 (s, 3 H, OMe), 2.81 (dq, $J = 3.0$ and 7.5 Hz, 1 H, NCHPr), 1.81 (dq, $J = 2.0$ and 7.5 Hz, 1 H, CHCHHCH), 1.67 (q, $J = 7.5$ Hz, 1 H, CHCHHCH), 1.00–0.80 (m, 2 H, CH_2CH_3), 0.78–0.67 (m, 2 H, $\text{CH}_2\text{CH}_2\text{CH}_3$), 0.49 (t, $J = 7.0$ Hz, 3 H, CH_3), 0.0 (s, 9 H, TMS) ppm. ^{13}C NMR (62.9 MHz, CDCl_3): $\delta = 140.7$, 128.7, 128.2, 127.6 (Ar), 77.5 (CH_2O), 71.0 (NCHPh), 62.2 (NCHCBr), 61.9 (NCHPr), 58.7 (OMe), 51.7 (CHBr), 37.8 ($\text{CH}_2\text{CH}_2\text{CH}_3$), 27.3 (CH_2), 18.0 ($\text{CH}_2\text{CH}_2\text{CH}_3$), 14.1 (CH_3), –2.0 (TMS) ppm. $\text{C}_{19}\text{H}_{32}\text{BrNOSi}$ (398.45): calcd. C 57.27, H 8.10; found C 57.89, H 8.30.

(2S,4R)-2-[(1S)-(Bromo)(trimethylsilyl)methyl]-4-isopropyl-1-[(1R)-2-methoxy-1-phenylethyl]azetidine (4c): Solid (36 mg, 43% yield). M.p. 63 °C. $[\alpha]_D^{20} = -41$ ($c = 1.0$, CHCl_3). ^1H NMR (250 MHz, CDCl_3): $\delta = 7.30\text{--}7.00$ (m, 5 H, Ar), 3.61–3.54 (m, 2 H, CHHO and CHBr), 3.45 (dd, $J = 3.5$ and 7.7 Hz, 1 H, NCHCBr), 3.28–3.17 (m, 2 H, CHHO and NCHPh), 3.15 (s, 3 H, OMe), 2.79 (dt, $J = 3.7$ and 8.5 Hz, 1 H, NCHiPr), 1.81 (q, $J = 10$ Hz, 1 H, CHCHHCH), 1.52 (dq, $J = 3.7$ and 10.0 Hz, 1 H, CHCHHCH),

0.73 (d, $J = 7.5$ Hz, 3 H, Me), 0.70–0.50 (m, 1 H, CHMe_2), 0.31 (d, $J = 7.5$ Hz, 3 H, Me), 0.0 (s, 9 H, TMS) ppm. ^{13}C NMR (62.9 MHz, CDCl_3): $\delta = 141.0$, 128.4, 128.2, 127.6 (Ar), 77.2 (CH_2O), 71.3 (NCHPh), 68.0 (NCHCBr), 61.0 (NCHiPr), 58.6 (OMe), 51.5 (CHBr), 30.0 (CHMe_2), 21.7 (CH_2), 18.4 (Me), 16.7 (Me), –2.0 (TMS) ppm. $\text{C}_{19}\text{H}_{32}\text{BrNOSi}$ (398.45): calcd. C 57.27, H 8.10, N 3.52; found C 57.32, H 8.71, N 3.82.

(2S,4R)-2-[(1S)-(Bromo)(trimethylsilyl)methyl]-4-tert-butyl-1-[(1R)-2-methoxy-1-phenylethyl]azetidine (4d): Oil (57 mg, 66% yield). $[\alpha]_D^{20} = -54$ ($c = 0.9$, CHCl_3). ^1H NMR (250 MHz, CDCl_3): $\delta = 7.41\text{--}7.37$ (m, 2 H, Ar), 7.25–7.05 (m, 3 H, Ar), 3.72 (dd, $J = 1.8$ and 7.8 Hz, 1 H, NCHCBr), 3.66 (dd, $J = 2.5$ and 8.0 Hz, 1 H, NCHPh), 3.54 (dd, $J = 8.0$ and 10.0 Hz, 1 H, CHHO), 3.36 (dd, $J = 3.5$ and 10.3 Hz, 1 H, CHHO), 3.34 (d, $J = 2.0$ Hz, 1 H, CHBr), 3.23 (s, 3 H, OMe), 2.88 (t, $J = 8.3$ Hz, 1 H, NCHtBu), 1.89–1.78 (m, 1 H, CHCHHCH), 1.69–1.58 (m, 1 H, CHCHHCH), 0.52 (s, 9 H, tBu), 0.0 (s, 9 H, TMS) ppm. ^{13}C NMR (62.9 MHz, CDCl_3): $\delta = 142.7$, 128.4, 128.1, 127.0 (Ar), 75.8 (CH_2O), 73.5 (NCHtBu), 68.4 (NCHPh), 58.6 (OMe), 57.4 (NCHCBr), 52.2 (CHBr), 34.4 (CMe_3), 26.5 (CMe_3), 23.8 (CH_2), –2.0 (TMS) ppm. $\text{C}_{20}\text{H}_{34}\text{BrNOSi}$ (412.48): calcd. C 58.24, H 8.31, N 3.40; found C 58.11, H 8.03, N 3.21.

General Procedure for the Preparation of the Bicyclic Compounds 5: A solution of tetrabutylammonium fluoride (1 M in THF, 0.45 mmol) was added dropwise to a solution of compound **3** (0.37 mmol) in THF (4 mL). The mixture was stirred at room temperature for 24 h. After the addition of water (5 mL), the solution was extracted with Et_2O . The organic layers were dried with MgSO_4 , filtered, and concentrated, and the crude product was flash-chromatographed.

(2R,6S,8R)-2,8-Diphenyl-4-oxa-1-azabicyclo[4.2.0]octane (5a): Oil (53 mg, 54% yield). $[\alpha]_D^{20} = -44$ ($c = 2.0$, CHCl_3). ^1H NMR (250 MHz, CDCl_3): $\delta = 7.17\text{--}6.89$ (m, 10 H, Ar), 4.04 (t, $J = 6.7$ Hz, 1 H, CHHO), 3.82 (dd, $J = 2.7$ and 9.5 Hz, 1 H, CHHO), 3.72–3.63 (m, 3 H, CHHO , CHHO and NCHPh), 3.56–3.51 (m, 1 H, NCHPh), 3.20–3.05 (m, 1 H, NCH), 2.31–2.23 (m, 2 H, CH_2) ppm. ^{13}C NMR (62.9 MHz, CDCl_3): $\delta = 141.4$, 137.4, 128.6, 128.3, 127.9, 127.8, 127.7, 127.3 (Ar), 73.6 (CH_2O), 70.7 (NCHPh), 69.6 (NCHPh), 69.4 (CH_2O), 61.5 (NCH), 35.4 (CH_2) ppm. $\text{C}_{18}\text{H}_{19}\text{NO}$ (265.35): calcd. C 81.47, H 7.22, N 5.28; found C 80.76, H 7.47, N 5.02.

(2R,6S,8S)-2-Phenyl-8-propyl-4-oxa-1-azabicyclo[4.2.0]octane (5b): Oil (46.2 mg, 54% yield). $[\alpha]_D^{20} = -93$ ($c = 1.8$, CHCl_3). ^1H NMR (250 MHz, CDCl_3): $\delta = 7.21\text{--}7.06$ (m, 5 H, Ar), 3.61 (dd, $J = 2.7$ and 9.5 Hz, 1 H, CHHO), 3.55 (dd, $J = 2.0$ and 9.7 Hz, 1 H, CHHO), 3.42 (t, $J = 9.7$ Hz, 1 H, CHHO), 3.38–3.28 (m, 2 H, NCHPh and CHHO), 3.04–2.93 (m, 1 H, NCHPr), 2.88–2.75 (m, 1 H, NCH), 1.91 (td, $J = 5.5$ and 8.7 Hz, 1 H, CHH), 1.63 (q, $J = 8.8$ Hz, 1 H, CHH), 1.15–0.50 (m, 4 H, $\text{CH}_2\text{CH}_2\text{CH}_3$), 0.53 (t, $J = 7.0$ Hz, 3 H, CH_3) ppm. ^{13}C NMR (62.9 MHz, CDCl_3): $\delta = 139.4$, 128.3, 128.2, 127.8 (Ar), 73.6 (CH_2O), 70.7 (CH_2O), 68.9 (NCHPh), 67.5 (NCHPr), 61.7 (NCH), 38.1 ($\text{CH}_2\text{CH}_2\text{CH}_3$), 32.9 (CH_2), 18.8 ($\text{CH}_2\text{CH}_2\text{CH}_3$), 14.2 (CH_3) ppm. $\text{C}_{15}\text{H}_{21}\text{NO}$ (231.33): calcd. C 77.88, H 9.15, N 6.05; found C 77.82, H 9.51, N .29.

(2R,6S,8R)-8-Isopropyl-2-phenyl-4-oxa-1-azabicyclo[4.2.0]octane (5c): Oil (47 mg, 55% yield). $[\alpha]_D^{20} = -90$ ($c = 1.5$, CHCl_3). ^1H NMR (250 MHz, CDCl_3): $\delta = 7.32\text{--}7.18$ (m, 5 H, Ar), 3.73 (dd, $J = 2.5$ and 9.5 Hz, 1 H, CHHO), 3.67–3.48 (m, 4 H, CH_2O , NCHPh and CHHO), 2.97–2.84 (m, 2 H, NCH and NCHiPr), 1.85–1.78 (m, 2 H, CH_2), 1.25–1.16 (m, 1 H, CHMe_2), 0.71 (d, $J = 6.7$ Hz, 3 H, Me), 0.33 (d, $J = 6.7$ Hz, 3 H, Me) ppm. ^{13}C NMR (62.9 MHz, CDCl_3): $\delta = 139.8$, 128.4, 128.3, 128.0 (Ar), 73.8 (NCHiPr), 73.5

(CH₂O), 70.6 (CH₂O), 69.7 (NCHPh), 61.3 (NCH), 30.5 (CHMe₂), 27.8 (CH₂), 19.5 (Me), 17.6 (Me) ppm.

(2R,6S,8R)-8-tert-Butyl-2-phenyl-4-oxa-1-azabicyclo[4.2.0]octane (5d): Oil (49 mg, 54% yield). $[\alpha]_D^{20} = -99$ ($c = 1.4$, CHCl₃). ¹H NMR (250 MHz, CDCl₃): $\delta = 7.21$ – 7.18 (m, 5 H, Ar), 3.70 (dd, $J = 2.5$ and 9.5 Hz, 1 H, CHHO), 3.66–3.40 (m, 4 H, CHHO, CH₂O and NCHPh), 2.85–2.74 (m, 2 H, NCH*t*Bu and NCHCH₂), 1.78–1.70 (m, 2 H, CH₂), 0.36 (s, 9 H, *t*Bu) ppm. ¹³C NMR (62.9 MHz, CDCl₃): $\delta = 139.7$, 128.6, 127.8, 127.6 (Ar), 78.3 (NCH*t*Bu), 72.7 (CH₂O), 70.1 (NCHPh), 69.9 (CH₂O), 60.6 (NCH), 31.6 (*Ct*Bu), 27.1 (CH₂), 25.8 (*Ct*Bu) ppm. C₁₆H₂₃NO (245.36): calcd. C 78.32, H 9.45, N 5.71; found C 78.02, H 9.61, N 5.42.

General Procedure for the Preparation of the Brominated β -Amino Alcohols 6 and β -Amino Ethers 7: A solution of hydrofluoric acid in pyridine (35 μ L) was added to a solution of azetidine (0.13 mmol) in THF (1.5 mL) at 0 °C. The mixture was stirred until the complete disappearance of the starting material. After the addition of saturated aq. NaHCO₃ (3 mL), the aqueous layer was extracted with Et₂O (3 $\times$ 3 mL). The organic layers were dried with MgSO₄, concentrated under reduced pressure, and compounds 6 and 7 were isolated.

(2R)-2-[(1R,3Z)-4-Bromo-1-phenylbut-3-en-1-yl]amino]-2-phenylethanol (6a): Oil (42.7 mg, 95% yield). $[\alpha]_D^{20} = -47$ ($c = 1.0$, CHCl₃). ¹H NMR (250 MHz, CDCl₃): $\delta = 7.26$ – 7.12 (m, 10 H, Ar), 6.08 (d, $J = 7.0$ Hz, 1 H, CH=CHBr), 5.85 (q, $J = 7.0$ Hz, 1 H, CH=CHBr), 3.83 (dd, $J = 4.7$ and 7.2 Hz, 1 H, NCHPh), 3.72–3.64 (m, 2 H, NCHPh and CHHO), 3.46 (dd, $J = 4.7$ and 7.2 Hz, 1 H, CHHO), 2.74–2.62 (m, 1 H, CHHC=C), 2.56–2.44 (m, 3 H, CHHC=C, OH and NH) ppm. ¹³C NMR (62.9 MHz, CDCl₃): $\delta = 143.2$, 140.9 (Ar), 131.3 (CH=CHBr), 128.7, 128.6, 127.7, 127.6, 127.3, 127.1 (Ar), 109.9 (CH=CHBr), 65.9 (CH₂O), 61.6 (NCHPh), 58.9 (NCHPh), 36.8 (CH₂C=C) ppm. C₁₈H₂₀BrNO (346.26): calcd. C 62.44, H 5.82, N 4.05; found C 62.82, H 5.96, N 3.84.

(2R)-2-[(1S,3Z)-4-Bromo-1-propylbut-3-en-1-yl]amino]-2-phenylethanol (6b): Oil (33.3 mg, 82% yield). $[\alpha]_D^{20} = -93$ ($c = 1.0$, CHCl₃). ¹H NMR (250 MHz, CDCl₃): $\delta = 7.35$ – 7.21 (m, 5 H, Ar), 6.19 (d, $J = 7.0$ Hz, 1 H, CH=CHBr), 6.10 (q, $J = 7.0$ Hz, 1 H, CH=CHBr), 3.86 (dd, $J = 4.5$ and 8.7 Hz, 1 H, NCHPh), 3.62 (dd, $J = 4.5$ and 10.7 Hz, 1 H, CHHO), 3.45 (dd, $J = 8.7$ and 10.7 Hz, 1 H, CHHO), 2.58–2.54 (m, 1 H, NCHPr), 2.30–2.25 (m, 4 H, CH₂C=C, OH and NH), 1.37–1.19 (m, 4 H, CH₂CH₂CH₃), 0.73 (t, $J = 6.0$ Hz, 3 H, CH₃) ppm. ¹³C NMR (62.9 MHz, CDCl₃): $\delta = 141.1$ (Ar), 131.6 (CH=CHBr), 128.8, 127.8, 127.3 (Ar), 109.7 (CH=CHBr), 67.0 (CH₂O), 61.8 (NCHPh), 53.2 (NCHPr), 37.4 (CH₂CH₂CH₃), 33.8 (CH₂C=C), 19.3 (CH₂CH₂CH₃), 14.2 (CH₂CH₂CH₃) ppm. C₁₅H₂₂BrNO (312.25): calcd. C 57.70, H 7.10, N 4.49; found C 58.19, H 7.40, N 4.34.

(2R)-2-[(1R,3Z)-4-Bromo-1-isopropylbut-3-en-1-yl]amino]-2-phenylethanol (6c): Oil (38.1 mg, 94% yield). $[\alpha]_D^{20} = -109$ ($c = 1.0$, CHCl₃). ¹H NMR (250 MHz, CDCl₃): $\delta = 7.31$ – 7.16 (m, 5 H, Ar), 6.16 (dt, $J = 1.0$ and 7.0 Hz, 1 H, CH=CHBr), 6.09 (q, $J = 6.7$ Hz, 1 H, CH=CHBr), 3.82 (dd, $J = 4.5$ and 8.5 Hz, 1 H, NCHPh), 3.60 (dd, $J = 4.5$ and 10.5 Hz, 1 H, CHHO), 3.45 (dd, $J = 8.7$ and 10.7 Hz, 1 H, CHHO), 2.38–2.26 (m, 3 H, NCH*i*Pr and CH₂C=C), 2.22 (br. s, 2 H, NH and OH), 1.64–1.51 (m, 1 H, CHMe₂), 0.82 (d, $J = 6.7$ Hz, 3 H, Me), 0.74 (d, $J = 6.7$ Hz, 3 H, Me) ppm. ¹³C NMR (62.9 MHz, CDCl₃): $\delta = 141.1$ (Ar), 132.3 (CH=CHBr), 128.7, 127.7, 127.5 (Ar), 109.3 (CH=CHBr), 67.0 (CH₂O), 62.0 (NCHPh), 59.1 (NCH*i*Pr), 31.3 (CH₂C=C), 31.1 (CHMe₂), 19.0 (Me), 18.4 (Me) ppm. C₁₅H₂₂BrNO (312.25): calcd. C 57.70, H 7.10, N 4.49; found C 58.43, H 7.20, N 4.19.

(2R)-2-[(1R,3Z)-4-Bromo-1-tert-butylbut-3-en-1-yl]amino]-2-phenylethanol (6d): Oil (36.4 mg, 86% yield). $[\alpha]_D^{20} = -99$ ($c = 0.9$, CHCl₃). ¹H NMR (250 MHz, CDCl₃): $\delta = 7.30$ – 7.16 (m, 5 H, Ar), 6.17 (q, $J = 6.7$ Hz, 1 H, CH=CHBr), 6.10 (d, $J = 7.2$ Hz, 1 H, CH=CHBr), 3.83 (dd, $J = 4.5$ and 8.5 Hz, 1 H, NCHPh), 3.60 (dd, $J = 4.7$ and 10.7 Hz, 1 H, CHHO), 3.46 (dd, $J = 8.5$ and 10.7 Hz, 1 H, CHHO), 2.43–2.25 (m, 2 H, CH₂C=C), 2.21 (t, $J = 4.7$ Hz, 1 H, NCH*t*Bu), 2.08 (br. s, 2 H, NH and OH), 0.79 (s, 9 H, *t*Bu) ppm. ¹³C NMR (62.9 MHz, CDCl₃): $\delta = 141.1$ (Ar), 134.2 (CH=CHBr), 128.7, 127.7 (Ar), 108.0 (CH=CHBr), 67.2 (NCHPh), 62.5 (NCH*t*Bu), 62.3 (CH₂O), 35.2 (CMe₃), 31.7 (CH₂C=C), 27.1 (CMe₃) ppm. C₁₆H₂₄BrNO (326.27): calcd. C 58.90, H 7.41, N 4.29; found C 58.61, H 7.48, N 4.07.

[(1R,3Z)-4-Bromo-1-phenylbut-3-en-1-yl][(1R)-2-methoxy-1-phenylethyl]amine (7a): Oil (45.4 mg, 97% yield). $[\alpha]_D^{20} = -35$ ($c = 2.1$, CHCl₃). ¹H NMR (250 MHz, CDCl₃): $\delta = 7.26$ – 7.08 (m, 10 H, Ar), 6.06 (dt, $J = 1.5$ and 6.7 Hz, 1 H, CH=CHBr), 5.85 (q, $J = 6.7$ Hz, 1 H, CH=CHBr), 3.94 (dd, $J = 5.0$ and 6.5 Hz, 1 H, NCHPh), 3.69 (dd, $J = 5.7$ and 7.5 Hz, 1 H, NCHPh), 3.35–3.28 (m, 2 H, CH₂O), 3.26 (s, 3 H, OMe), 2.70–2.68 (m, 1 H, CHHC=C), 2.52–2.48 (m, 1 H, CHHC=C), 2.30 (br. s, 1 H, NH) ppm. ¹³C NMR (62.9 MHz, CDCl₃): $\delta = 143.4$, 141.1 (Ar), 131.6 (CH=CHBr), 128.5, 127.8, 127.5, 127.4, 127.2 (Ar), 109.6 (CH=CHBr), 77.2 (CH₂O), 60.2 (NCHPh), 59.1 (NCHPh), 59.0 (OMe), 36.6 (CH₂C=C) ppm. C₁₉H₂₂BrNO (360.29): calcd. C 63.34, H 6.15, N 3.89; found C 63.39, H 7.07, N 4.04.

[(1S,3Z)-4-Bromo-1-propylbut-3-en-1-yl][(1R)-2-methoxy-1-phenylethyl]amine (7b): Oil (39 mg, 92% yield). $[\alpha]_D^{20} = -83$ ($c = 1.0$, CHCl₃). ¹H NMR (250 MHz, CDCl₃): $\delta = 7.33$ – 7.18 (m, 5 H, Ar), 6.16 (dd, $J = 1.2$ and 6.2 Hz, 1 H, CH=CHBr), 6.06 (q, $J = 6.2$ Hz, 1 H, CH=CHBr), 4.01 (t, $J = 6.2$ Hz, 1 H, NCHPh), 3.38–3.31 (m, 2 H, CH₂O), 3.27 (s, 3 H, OMe), 2.46–2.39 (m, 1 H, NCHPr), 2.27–2.23 (m, 3 H, CH₂C=C and NH), 1.36–1.18 (m, 4 H, CH₂CH₂CH₃), 0.72 (t, $J = 7.5$ Hz, 3 H, CH₃) ppm. ¹³C NMR (62.9 MHz, CDCl₃): $\delta = 141.1$ (Ar), 131.7 (CH=CHBr), 128.5, 127.9, 127.5 (Ar), 109.5 (CH=CHBr), 78.0 (CH₂O), 59.5 (NCHPh), 58.9 (OMe), 52.9 (NCHPr), 37.6 (CH₂C=C), 33.5 (CH₂CH₂CH₃), 19.3 (CH₂CH₂CH₃), 14.2 (CH₃) ppm. C₁₆H₂₄BrNO (326.27): calcd. C 58.90, H 7.41, N 4.29; found C 59.31, H 7.53, N 4.14.

[(1R,3Z)-4-Bromo-1-isopropylbut-3-en-1-yl][(1R)-2-methoxy-1-phenylethyl]amine (7c): Oil (21.2 mg, 50% yield). $[\alpha]_D^{20} = -87$ ($c = 1.0$, CHCl₃). ¹H NMR (250 MHz, CDCl₃): $\delta = 7.33$ – 7.15 (m, 5 H, Ar), 6.12 (td, $J = 1.2$ and 7.0 Hz, 1 H, CH=CHBr), 6.03 (q, $J = 6.5$ Hz, 1 H, CH=CHBr), 3.99 (t, $J = 6.5$ Hz, 1 H, NCHPh), 3.34 (d, $J = 6.5$ Hz, 2 H, CH₂O), 3.28 (s, 3 H, OMe), 2.35–2.18 (m, 3 H, CH₂C=C and NCH*i*Pr), 1.56 (br. s, 1 H, NH), 1.54–1.47 (m, 1 H, CHMe₂), 0.82 (d, $J = 6.7$ Hz, 3 H, Me), 0.77 (d, $J = 6.7$ Hz, 3 H, Me) ppm. ¹³C NMR (62.9 MHz, CDCl₃): $\delta = 141.5$ (Ar), 132.5 (CH=CHBr), 128.3, 128.1, 127.5 (Ar), 108.9 (CH=CHBr), 78.2 (CH₂O), 59.8 (NCHPh), 58.9 (NCH*i*Pr), 58.7 (OMe), 31.3 (CH₂C=C and CHMe₂), 19.7 (Me), 18.0 (Me) ppm. C₁₆H₂₄BrNO (326.27): calcd. C 58.90, H 7.41, N 4.29; found C 58.49, H 7.64, N 3.77.

[(1R,3Z)-4-Bromo-1-tert-butylbut-3-en-1-yl][(1R)-2-methoxy-1-phenylethyl]amine (7d): Oil (42 mg, 95% yield). $[\alpha]_D^{20} = -100$ ($c = 1.0$, CHCl₃). ¹H NMR (250 MHz, CDCl₃): $\delta = 7.36$ – 7.19 (m, 5 H, Ar), 6.19 (q, $J = 7.0$ Hz, 1 H, CH=CHBr), 6.11 (d, $J = 7.0$ Hz, 1 H, CH=CHBr), 4.01 (dd, $J = 4.7$ and 8.0 Hz, 1 H, NCHPh), 3.41–3.37 (m, 2 H, CH₂O), 3.33 (s, 3 H, OMe), 2.51–2.41 (m, 1 H, CHHC=C), 2.38–2.25 (m, 1 H, CHHC=C), 2.13 (t, $J = 5.0$ Hz, 1 H, NCH*t*Bu), 1.68 (br. s, 1 H, NH), 0.84 (s, 9 H, *t*Bu) ppm. ¹³C NMR (62.9 MHz, CDCl₃): $\delta = 141.2$ (Ar), 134.5 (CH=CHBr),

128.4, 128.3, 127.5 (Ar), 107.5 (CH=CHBr), 78.2 (CH₂O), 61.9 (NCH*t*Bu), 60.1 (NCHPh), 58.9 (OMe), 35.5 (CMe₃), 31.6 (CH₂C=C), 27.2 (CMe₃) ppm.


(2*R*,4*S*)-2-*tert*-Butyl-4-[(trimethylsilyl)methyl]azetidine Hydrobromide (8): A solution of compound **3d** (0.13 mmol) in absolute ethanol (1.5 mL) was injected into a hydrogenation flask containing a suspension of palladium on charcoal (15 mg) in absolute ethanol (1 mL). The reaction was complete in 3 h. The mixture was filtered through Celite 545, and the residue was washed with ethanol. After evaporation of the solvent, the resulting solid was triturated with Et₂O and dried to afford the azetidine **8**. Solid (18.2 mg, 50% yield). M.p. 70 °C. [α]_D²⁰ = -6 (*c* = 1.44, CHCl₃). ¹H NMR (250 MHz, CD₃OD): δ = 4.39–4.25 (m, 1 H, NCHCH₂TMS), 3.99 (t, *J* = 10 Hz, 1 H, NCH*t*Bu), 2.43 (dt, *J* = 8.0 and 11.8 Hz, 1 H, CHCHHCH), 2.13–2.00 (m, 1 H, CHCHHCH), 1.19–1.04 (m, 2 H, CH₂TMS), 0.90 (s, 9 H, *t*Bu), 0.00 (s, 9 H, TMS) ppm. ¹³C NMR (62.9 MHz, CDCl₃): δ = 64.8 (NCH*t*Bu), 54.7 (NCHCH₂TMS), 32.5 (CMe₃), 29.5 (CHCH₂CH), 25.1 (CMe₃), 23.7 (CH₂TMS), -1.0 (TMS) ppm. C₁₁H₂₆BrNSi (280.32): calcd. C 47.13, H 9.35, N 5.00; found C 47.23, H 9.56, N 4.87.

Supporting Information (see footnote on the first page of this article): ¹H and ¹³C NMR spectra of obtained compounds and AM1-calculated structures for bromonium and azetidinium ions.

Acknowledgments

We thank Dr. Patrick Herson for X-ray analyses of compounds **4d** and **5a**.

- [1] For recent examples of *O*-cyclizations, see: a) G. Fragale, T. Wirth, *Eur. J. Org. Chem.* **1998**, 1361; b) M. Gruttadauria, P. Lo Meo, R. Noto, *Tetrahedron* **2001**, *57*, 1819; c) P. Van de Weghe, S. Bourg, J. Eustache, *Tetrahedron* **2003**, *59*, 7365; d) S. Ma, L. Lu, *J. Org. Chem.* **2005**, *70*, 7629; e) L. A. Paquette, I. H. Kim, N. Cunière, *Org. Lett.* **2003**, *5*, 221; f) R. Pedrosa, C. Andrés, P. Mendiguchia, J. Nieto, *J. Org. Chem.* **2006**, *71*, 8854, and references therein.
- [2] For recent examples of *N*-cyclizations, see: a) N. De Kimpe, D. De Smaele, *J. Heterocycl. Chem.* **2000**, *37*, 607; b) X. Pannecoucke, F. Outurquin, C. Paulmier, *Eur. J. Org. Chem.* **2002**, 995; c) F. Outurquin, X. Pannecoucke, B. Berthe, C. Paulmier, *Eur. J. Org. Chem.* **2002**, 1007; d) D. W. Knight, A. L. Redfern, J. Gilmore, *J. Chem. Soc. Perkin Trans. 1* **2001**, 2874; e) D. W. Knight, A. L. Redfern, J. Gilmore, *J. Chem. Soc. Perkin Trans. 1* **2002**, 622; f) S. Robin, G. Rousseau, *Eur. J. Org. Chem.* **2000**, 3007; g) E. J. Corey, T.-P. Loh, S. AchyuthaRao, D. C. Daley, S. Sarshar, *J. Org. Chem.* **1993**, *58*, 5600; h) B. Berthe, F. Outurquin, C. Paulmier, *Tetrahedron Lett.* **1997**, *38*, 1393; i) S. Minakata, Y. Morino, Y. Oderaotoshi, M. Komatsu, *Org. Lett.* **2006**, *8*, 3335.
- [3] For examples of silicon-directed *O*-cyclizations, see: a) K. Miura, T. Hondo, H. Saito, H. Ito, A. Hosomi, *J. Org. Chem.* **1997**, *62*, 8292; b) K. Miura, T. Hondo, S. Okajima, A. Hosomi, *Tetrahedron Lett.* **1996**, *37*, 487; c) E. Schaumann, A. Kirschning, *J. Chem. Soc. Perkin Trans. 1* **1990**, 1481; d) K. Miura, T. Hondo, S. Okajima, T. Nakagawa, T. Takahashi, A. Hosomi, *J. Am. Chem. Soc.* **2000**, *122*, 11348; e) K. Miura, S. Okajima, T. Hondo, T. Nakagawa, T. Takahashi, A. Hosomi, *J. Org. Chem.* **2002**, *67*, 6082; f) M. Rofoo, M.-C. Roux, G. Rousseau, *Tetrahedron Lett.* **2001**, *42*, 2481; g) G. Adiwidjaja, H. Flörke, A. Kirschning, E. Schaumann, *Liebigs Ann. Chem.* **1995**, 501; h) E. Ehlinger, P. Magnus, *J. Am. Chem. Soc.* **1980**, *102*, 5004; i) L. A. Paquette, I. H. Kim, N. Cunière, *Org. Lett.* **2003**, *5*, 221.
- [4] For examples of silicon-directed *N*-cyclizations, see: a) K. Miura, T. Hondo, T. Nakagawa, T. Takahashi, A. Hosomi, *Org. Lett.* **2000**, *2*, 385; b) H. Hasegawa, H. Senboku, Y. Kajizuka, K. Orito, M. Tokuda, *Tetrahedron* **2003**, *59*, 827; c) K. Miura, T. Takahashi, T. Hondo, A. Hosomi, *Chirality* **2003**, *15*, 41.
- [5] a) C. Agami, S. Comesse, C. Kadouri-Puchot, *J. Org. Chem.* **2002**, *67*, 2424; b) C. Agami, S. Comesse, S. Guesné, C. Kadouri-Puchot, L. Martinon, *Synlett* **2003**, 1058; c) C. Agami, S. Comesse, C. Kadouri-Puchot, *J. Org. Chem.* **2002**, *67*, 1496.
- [6] Preliminary communication: V. Lemau de Talancé, E. Banide, B. Bertin, S. Comesse, C. Kadouri-Puchot, *Tetrahedron Lett.* **2005**, *46*, 8023.
- [7] For reviews, see: a) N. De Kimpe, in *Comprehensive Heterocyclic Chemistry II* (Eds.: A. Padwa), Elsevier, Oxford, **1996**, vol. 1B, chapter 1.18, pp. 507–589; b) F. Couty, G. Evano, D. Prim, *Mini-Rev. Org. Chem.* **2004**, *1*, 133; c) S. Robin, G. Rousseau, *Eur. J. Org. Chem.* **2002**, 3099.
- [8] a) R. Pedrosa, C. Andrés, J. Nieto, S. del Pozo, *J. Org. Chem.* **2005**, *70*, 1408; b) S. Mangelinckx, M. Boeykens, M. Vliegen, J. Van der Eycken, N. De Kimpe, *Tetrahedron Lett.* **2005**, *46*, 525; c) D. Enders, J. Gries, Z.-S. Kim, *Eur. J. Org. Chem.* **2004**, 4471; d) F. Couty, G. Evano, N. Rabasso, *Tetrahedron: Asymmetry* **2003**, *14*, 2407; e) A. C. B. Burtoloso, C. R. D. Correia, *Tetrahedron Lett.* **2004**, *45*, 3355; f) D. Enders, J. Gries, *Synthesis* **2005**, 3508; g) S.-H. Ma, D. H. Yoon, H.-J. Ha, W. K. Lee, *Tetrahedron Lett.* **2007**, *48*, 269; h) R. Marcia de Figueredo, R. Frölich, M. Christmann, *J. Org. Chem.* **2006**, *71*, 4147; i) A. Marinetti, P. Hubert, J.-P. Genêt, *Eur. J. Org. Chem.* **2000**, 1815.
- [9] CCDC-641472 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif.
- [10] This solvent was already reported as the more efficient solvent for a 4-*exo* trig process: ref.^[2b,2h]
- [11] J. E. Baldwin, *J. Chem. Soc. Chem. Commun.* **1976**, 734.
- [12] AM1 calculations: The calculations on the bromonium intermediate were carried out using the AM1 Hamiltonian^[13] as implemented in the AMPAC program version 4.0 QCPE No527. The geometries were optimized by using the Davidson–Fletcher–Powell algorithm (FLEPO procedure) that minimizes the energy with respect to all internal coordinates.
- [13] A. Sevin, J. Tortajada, M. Pfau, *J. Org. Chem.* **1986**, *51*, 2671.
- [14] J. B. Lambert, Y. Zhao, R. W. Emblidge, L. A. Salvador, X. Liu, J.-H. So, E. C. Chelius, *Acc. Chem. Res.* **1999**, *32*, 183.
- [15] These calculations excluded any other configuration for the nitrogen atom. Any attempt at optimisation led to the stable configuration proposed here.
- [16] In this mixture, a new product was isolated. The NMR spectra are in accordance with either the brominated azetidine or pyrrolidine. As described in ref.^[17], α -halo azetidines are known to be unstable and rearrange to pyrrolidines:



[17] F. Couty, F. Durrat, D. Prim, *Tetrahedron Lett.* **2003**, *44*, 5209.

[18] CCDC-641473 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif.

[19] The (*Z*) configuration was based upon the coupling (7.0 Hz) of the ethylene hydrogen atoms.

[20] For an *anti* elimination of β -silyl azides, see: L. Chabaud, Y. Landais, *Tetrahedron Lett.* **2003**, *44*, 6995.

[21] For references concerning the utility of vinylsilanes as intermediates in the stereoselective synthesis of vinyl halides, see: a) M. A. Brook, M. A. Hadi, A. Neuy, *J. Chem. Soc. Chem. Commun.* **1989**, 957; b) K. E. Koenig, W. P. Weber, *Tetrahedron Lett.*

- 1973, 14, 2533; c) R. B. Miller, G. McGarvey, *J. Org. Chem.* **1978**, 43, 4424.
- [22] For an example of the ring opening of azetidinium ions by a β -elimination, see: G. Gionta, C. Lillocci, *J. Phys. Org. Chem.* **1993**, 6, 187.
- [23] For a reference concerning the S_N2' ring opening of four-membered cyclic ammonium ions, see: F. Couty, F. Durrat, G. Evano, J. Marrot, *Eur. J. Org. Chem.* **2006**, 4214.

Received: March 30, 2007
Published Online: July 12, 2007